¼¼°èÀÇ ¾È±¸ Èæ»öÁ¾ ½ÃÀå º¸°í¼­(2025³â)
Eye Melanoma Global Market Report 2025
»óǰÄÚµå : 1686375
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,242,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,023,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,803,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¾È±¸ Èæ»öÁ¾ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ °­·ÂÇÑ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â 137¾ï 7,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, CAGR 8.6%·Î ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ¼ºÀåÀº Áö¼ÓÀûÀÎ °øÁß º¸°Ç¿¡ ´ëÇÑ ³ë·Â, À¯ÀüÀÚ ¹× ºÐÀÚ ÇÁ·ÎÆÄÀϸµ Á¶»ç, ¼¼°èÀÇ ³ëÈ­ µ¿Çâ¿¡ ±âÀÎÇÕ´Ï´Ù. ¿¹Ãø ±â°£ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ÀΰøÁö´É(AI)ÀÇ ÅëÇÕ, Ç¥Àû Ä¡·áÀÇ ÃâÇö, Èñ±ÍÁúȯ Ä¡·áÁ¦ °³¹ß¿¡ ÁÖ·Â, ȯÀÚ Áß½ÉÀÇ ÀǾàǰ ½ÂÀÎ ÇÁ·Î¼¼½º, ¿µ»ó Áø´ÜÀÇ Áøº¸, Ä¡·á ¹æ¹ýÀÇ Áøº¸, ¿µ»ó Áø´ÜÀÇ ±â¼ú Çõ½Å µîÀÌ ÀÖ½À´Ï´Ù.

¿¹ÃøµÇ´Â ¾È¾Ï ȯÀÚ Áõ°¡´Â ÇâÈÄ ¼ö³â°£ ¾È±¸ Èæ»öÁ¾ ½ÃÀå È®´ëÀÇ Áß¿äÇÑ ÃËÁø¿äÀÎÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾È¾ÏÀº ¾È±¸ ±¸Á¶¿¡¼­ ¼¼Æ÷ÀÇ ºñÁ¤»óÀûÀ̰í ÅëÁ¦ ºÒ°¡´ÉÇÑ Áõ½ÄÀ» ³ªÅ¸³À´Ï´Ù. ¹ß°ß ±â¼úÀÇ °­È­, ÀÎÁöµµÀÇ Çâ»ó, Ä¡·á ¿É¼ÇÀÇ Áøº¸¿¡ ÀÇÇØ ÃʱâÀÇ Áõ·Ê¸¦ È¿°úÀûÀ¸·Î °ü¸®Çϱâ À§ÇÑ Àü¹®ÀûÀÎ Ä¡·á³ª °³ÀÔ¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹¾ÏÇùȸÀÇ 2023³â 1¿ù º¸°í¼­¿¡ µû¸£¸é ¾È±¸ ¹× ¾È¿Í¾ÏÀÇ Áõ·Ê´Â 2023³â¿¡´Â 3,490°ÇÀ¸·Î Áõ°¡ÇÏ¿´À¸¸ç, 2021³â 3,320°Ç¿¡¼­ 5.12%ÀÇ ¼ºÀåÀ» º¸¿´½À´Ï´Ù. µû¶ó¼­ ¾È±¸¾Ï Áõ·ÊÀÇ ±ÞÁõÀÌ ¾È±¸ Èæ»öÁ¾ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

³ëÀÎ Àα¸ Áõ°¡°¡ ¿¹»óµÊ¿¡ µû¶ó ¾È±¸ Èæ»öÁ¾ ½ÃÀåÀÇ È®´ë°¡ ´çºÐ°£ ¿¹»óµË´Ï´Ù. ¾È±¸¾ÏÀÇ ÀÏÁ¾ÀÎ ¾È±¸ Èæ»öÁ¾Àº °í·ÉÀÚ°¡ ȯ°æ¿äÀÎÀ̳ª À¯ÀüÀû ¼ÒÀο¡ Àå±â°£ ³ëÃâµÊ¿¡ µû¶ó ³ëÈ­¿Í ÇÔ²² À¯ÇàÇÏ´Â °æÇâÀÌ ÀÖ½À´Ï´Ù. ³ëÀÎÀÇ Àα¸ Áõ°¡·Î ÀÎÇØ ¾È±¸ Èæ»öÁ¾À» ¾ÎÀ» ¼ö ÀÖ´Â »ç¶÷ÀÇ ¼ö°¡ Áõ°¡ÇÕ´Ï´Ù. 2022³â 10¿ù ¼¼°èº¸°Ç±â±¸(WHO)°¡ º¸°íÇÑ °Íó·³ 60¼¼ ÀÌ»óÀÇ Àα¸´Â 2021³â 10¾ï ¸í¿¡¼­ 2022³â 14¾ï ¸íÀ¸·Î ±ÞÁõÇÏ¿´°í, 2050³â¿¡´Â 21¾ï ¸íÀ¸·Î µÎ¹è·Î µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±×·¯¹Ç·Î ³ë³â Àα¸ Áõ°¡´Â ¾È±¸ Èæ»öÁ¾ ½ÃÀåÀÇ ¼ºÀåÀ» À̲ø °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ ¹× Àü·«

Á¦4Àå ½ÃÀå-±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, Äڷγª, ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼® ¹× Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ ¹× ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å· ¹× ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹® ¹× Àü·«

Á¦36Àå ºÎ·Ï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Eye melanoma is a form of cancer that develops in the melanocytes, the cells responsible for producing melanin within the eye. This cancer can manifest in different parts of the eye, including the uvea, iris, and choroid. Eye melanoma stands as the most common primary intraocular cancer in adults and may lead to vision issues, alterations in eye color, and other symptoms, depending on its location and size.

The primary types of eye melanoma are found in the uvea, sclera, and retina. The uvea constitutes the middle layer of the eye, encompassing the iris, ciliary body, and choroid, housing blood vessels that supply nutrients to the eye. Various forms of radiation therapy, such as plaque brachytherapy, proton beam therapy, and stereotactic radiosurgery, are employed to target and reduce the size of uveal melanomas. Diagnosis involves imaging, biopsy, and eye examinations, while treatments include surgery, radiation therapy, targeted therapy, immunotherapy, and other approaches. These treatments are typically administered by end users such as hospitals, clinics, and academic institutes.

The eye melanoma market research report is one of a series of new reports from The Business Research Company that provides eye melanoma market statistics, including eye melanoma industry global market size, regional shares, competitors with an eye melanoma market share, detailed eye melanoma market segments, market trends and opportunities, and any further data you may need to thrive in the eye melanoma industry. This eye melanoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The eye melanoma market size has grown strongly in recent years. It will grow from $9.1 billion in 2024 to $9.89 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to increased awareness and early detection, aging population and sun exposure, rise in skin cancer incidence, development of targeted therapies, patient advocacy and support programs.

The eye melanoma market size is expected to see strong growth in the next few years. It will grow to $13.77 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to continued public health initiatives, research in genetic and molecular profiling, global aging population trends. Major trends in the forecast period include integration of artificial intelligence (ai), emergence of targeted therapies, focus on rare disease drug development, patient-centric drug approval processes, advancements in diagnostic imaging, advancements in treatment modalities, technological innovations in imaging.

The projected rise in eye cancer cases is poised to be a significant driver for the eye melanoma market's expansion in the coming years. Eye cancer denotes the abnormal and uncontrolled growth of cells within the eye's structures. Enhanced detection techniques, increased awareness, and advancements in treatment options have led to a heightened demand for specialized therapies and interventions to effectively manage early cases. For example, according to the American Cancer Society's January 2023 report, eye and orbital cancer cases increased to 3,490 in 2023, marking a 5.12% growth from 3,320 in 2021. Therefore, the surge in eye cancer cases is expected to fuel the growth of the eye melanoma market.

The anticipated growth in the geriatric population is set to boost the eye melanoma market's expansion in the foreseeable future. Eye melanoma, a form of eye cancer, tends to become more prevalent with age due to prolonged exposure to environmental factors and genetic predispositions among older individuals. The expanding population of older adults increases the potential number of individuals susceptible to eye melanoma. As reported by the World Health Organization in October 2022, the population aged 60 and above surged from 1 billion in 2021 to 1.4 billion in 2022, with projections to double to 2.1 billion by 2050. Hence, the growing geriatric population is expected to drive the growth of the eye melanoma market.

Companies at the forefront of the eye melanoma treatment sector are dedicated to pioneering innovative and specialized treatments, particularly immunotherapies and targeted therapies, aiming to elevate patient outcomes and improve their quality of life. These novel treatment modalities have recently made significant strides in the field of oncology. For example, in January 2022, Immunocore Ltd., a UK-based biopharmaceutical firm specializing in soluble T-cell receptor technology for biological drug development, obtained approval from the U.S. Food and Drug Administration (FDA) for Kimmtrak (tebentafusp-tabn). This groundbreaking therapy, the first of its kind for individuals with unresectable or metastatic uveal melanoma (mUM), operates as an immunotherapy targeting the gp100 protein found on the surface of uveal melanoma cells. By activating the patient's immune system through engineered T-cell receptors, Kimmtrak enables a precision-focused approach to eliminating melanoma, leveraging specialized immune cells for cancer treatment.

In January 2023, Health Network One, a leading US-based specialty benefit management company, acquired Premier Eye Care for an undisclosed amount. This acquisition enables Health Network One to broaden its provider network, improve clinical quality, and foster innovation in ophthalmology services. Premier Eye Care, a US-based company, specializes in diagnosing and treating eye melanoma through various methods such as surgery, radiation, and laser therapy.

Major companies operating in the eye melanoma market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Koninklijke Philips N.V., Carl Zeiss AG, Genentech Inc., Elekta Instrument AB, Brainlab AG, Optos Plc, Castle Biosciences Inc., Heidelberg Engineering, Nektar Therapeutics, RaySearch Laboratories AB, Nidek Co. Ltd., IDEAYA Biosciences, Immunocore Limited, Topcon Healthcare, Oraya Therapeutics Inc., Delcath Systems Inc.

North America was the largest region in the eye melanoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eye melanoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the eye melanoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The eye melanoma market consists of revenues earned by entities by providing fine needle aspiration (FNA) techniques, blood testing, and genetic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The eye melanoma market also includes sales of drugs and therapeutics such as chemotherapy, cryotherapy, and photodynamic therapy (PDT). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Eye Melanoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on eye melanoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for eye melanoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The eye melanoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Eye Melanoma Market Characteristics

3. Eye Melanoma Market Trends And Strategies

4. Eye Melanoma Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Eye Melanoma Growth Analysis And Strategic Analysis Framework

6. Eye Melanoma Market Segmentation

7. Eye Melanoma Market Regional And Country Analysis

8. Asia-Pacific Eye Melanoma Market

9. China Eye Melanoma Market

10. India Eye Melanoma Market

11. Japan Eye Melanoma Market

12. Australia Eye Melanoma Market

13. Indonesia Eye Melanoma Market

14. South Korea Eye Melanoma Market

15. Western Europe Eye Melanoma Market

16. UK Eye Melanoma Market

17. Germany Eye Melanoma Market

18. France Eye Melanoma Market

19. Italy Eye Melanoma Market

20. Spain Eye Melanoma Market

21. Eastern Europe Eye Melanoma Market

22. Russia Eye Melanoma Market

23. North America Eye Melanoma Market

24. USA Eye Melanoma Market

25. Canada Eye Melanoma Market

26. South America Eye Melanoma Market

27. Brazil Eye Melanoma Market

28. Middle East Eye Melanoma Market

29. Africa Eye Melanoma Market

30. Eye Melanoma Market Competitive Landscape And Company Profiles

31. Eye Melanoma Market Other Major And Innovative Companies

32. Global Eye Melanoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Eye Melanoma Market

34. Recent Developments In The Eye Melanoma Market

35. Eye Melanoma Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â